Syndax Pharmaceuticals/$SNDX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Syndax Pharmaceuticals
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
- Ticker
- $SNDX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 298
- Headquarters
- New York, United States
- Website
- syndax.com
SNDX Metrics
BasicAdvanced
$859M
-
-$2.37
0.45
-
Price and volume
Market cap
$859M
Beta
0.45
52-week high
$25.59
52-week low
$9.15
Average daily volume
3.5M
Financial strength
Current ratio
4.691
Quick ratio
4.274
Long term debt to equity
-34.278
Total debt to equity
-34.308
Interest coverage (TTM)
-3.79%
Profitability
EBITDA (TTM)
-178.622
Gross margin (TTM)
-2.03%
Net profit margin (TTM)
-72.32%
Operating margin (TTM)
-61.67%
Revenue per employee (TTM)
$970,000
Management effectiveness
Return on assets (TTM)
-17.94%
Return on equity (TTM)
-426.43%
Valuation
Price to revenue (TTM)
2.914
Price to book
-49.97
Price to tangible book (TTM)
-49.97
Price to free cash flow (TTM)
-4.757
Free cash flow yield (TTM)
-21.02%
Free cash flow per share (TTM)
-2.005
Growth
Revenue change (TTM)
160.26%
Earnings per share change (TTM)
-34.25%
10-year revenue growth (CAGR)
72.80%
3-year earnings per share growth (CAGR)
-2.95%
10-year earnings per share growth (CAGR)
-6.15%
What the Analysts think about SNDX
Analyst ratings (Buy, Hold, Sell) for Syndax Pharmaceuticals stock.
Analyst projections of the future price of Syndax Pharmaceuticals stock.
Bulls say / Bears say
Revuforj revenue rose 90% year on year to $60.7 million in Q3 2026, with new patient starts up 20% quarter on quarter. More patients resuming treatment after transplants may also extend time on therapy. (Syndax Pharmaceuticals)
Niktimvo sales grew 47% year on year to $67.4 million in Q3, contributing $22.6 million in collaboration revenue to Syndax. This gives the company a second growing commercial revenue stream alongside Revuforj. (Syndax Pharmaceuticals)
Early phase 1 results for revumenib with intensive chemotherapy in newly diagnosed AML showed a 97% composite remission rate among 35 patients. If confirmed in larger studies, use in earlier-stage disease could broaden Revuforj’s reach; durability data are still immature. (Syndax Pharmaceuticals)
Axatilimab’s Phase 2 trial in idiopathic pulmonary fibrosis missed its primary endpoint, and Syndax has stopped developing it for that condition. This removes a potential growth opportunity for the drug. (Syndax Pharmaceuticals)
Syndax remained loss-making in Q3, with a $49.4 million net loss and $111.2 million in research, development and administrative expenses. Rising sales have not yet established profitability, while substantial spending continues. (Syndax Pharmaceuticals)
A competing menin inhibitor is giving leukaemia doctors another treatment option, and reporting has flagged early signs that this could limit Revuforj’s market-share gains. The effect of competition on future growth remains uncertain. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
SNDX Financial Performance
Revenues and expenses
SNDX Earnings Performance
Company profitability
Upcoming events
No upcoming events
SNDX News
AllArticlesVideos
Funds containing SNDX
Fund name | Fund size | $SNDX weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.6B | 0.08% |
iShares Healthcare Innovation$HEAL | $1.6B | 0.08% |
iShares Healthcare Innovation€2B78 | $1.6B | 0.08% |
iShares Ageing Population€AGED | $887M | 0.07% |
iShares Ageing Population£AGES | $887M | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.